Selexipag
Selexipag, sold as Uptravi, is a prostacyclin receptor agonist. The US label lists treating pulmonary arterial hypertension (PAH, WHO Group I): in adults, to delay disease progression and lower the risk of hospital admission for PAH, and, separately, in pediatric patients aged two years and older, where the label says it reduces NT-proBNP (natriuretic peptide) and is expected to delay disease progression and lower the risk of hospital admission for PAH. The label says the medicine acts as an agonist at the prostacyclin receptor and is structurally distinct from prostacyclin.
Also called UPTRAVI
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 1729002; UNII 5EXC0E384L. MeSH has no descriptor for selexipag (name lookups on 2026-11-18 found only a supplementary concept term), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class Prostacyclin Receptor Agonist, so the record is filed under the prostacyclin pathway page. The label read is the Actelion Pharmaceuticals US, Inc. label for Uptravi, applications NDA207947 and NDA214275, effective 2026-05-28 in openFDA. The adult and pediatric statements sit in separate claims and contexts. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says selexipag is a prostacyclin receptor (IP receptor) agonist that is structurally distinct from prostacyclin.
Claims and evidence
Context Adults with pulmonary arterial hypertension, as described in the US label of Uptravi
- Recipient
- Adult
- Population
- Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Excluded
- None stated
The US label of Uptravi (selexipag, Actelion Pharmaceuticals US, Inc., applications NDA207947 and NDA214275; the version dated 2026-05-28 in openFDA) describes selexipag as a prostacyclin receptor agonist. It lists treating pulmonary arterial hypertension (PAH, WHO Group I) in adults to delay disease progression and lower the risk of hospital admission for PAH.
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Uptravi
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA207947.
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260528.
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SEL-LB-04, Q-K30-SEL-LB-05).
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi
- Recipient
- Child
- Population
- Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Pediatric patients aged two years and older, as the label states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Excluded
- None stated
The same US label of Uptravi separately lists treating pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged two years and older. The label says Uptravi reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH.
Applies to Child Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi
- Certainty method
- Not assessed
- Limitations
- The label words the pediatric benefit as expected, and this claim keeps that wording. It is not a finding about how well the medicine works in children. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA207947.
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260528.
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SEL-LB-06, Q-K30-SEL-LB-07).
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In newborns, infants and children 1
The same US label of Uptravi separately lists treating pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged two years and older. The label says Uptravi reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH.
Applies to Child Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi
Population, setting and follow-up
- Pediatric patients aged two years and older with pulmonary arterial hypertension (PAH, WHO Group I), as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients aged two years and older, as the label states
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- The label words the pediatric benefit as expected, and this claim keeps that wording. It is not a finding about how well the medicine works in children. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA207947.
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260528.
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SEL-LB-06, Q-K30-SEL-LB-07).
- Retrieved
- Source effective date
- 2026-05-28
- Source state
- Current
- Version fingerprint
7b352ee0cb603b1ff8dc9159c9546084fb7ec91304d1ec90e2bc24639d387041- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists pulmonary arterial hypertension (WHO Group I) in adults, to delay disease progression and lower the risk of hospital admission for PAH, as an indication: Pulmonary arterial hypertension
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Uptravi
The US label of Uptravi (selexipag, Actelion Pharmaceuticals US, Inc., applications NDA207947 and NDA214275; the version dated 2026-05-28 in openFDA) describes selexipag as a prostacyclin receptor agonist. It lists treating pulmonary arterial hypertension (PAH, WHO Group I) in adults to delay disease progression and lower the risk of hospital admission for PAH.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The label also lists a pediatric use, which sits in a separate claim.
-
Claim, not a settled fact FDA label separately lists pulmonary arterial hypertension in pediatric patients aged two years and older as an indication: Pulmonary arterial hypertension
Applies to Child Pediatric patients aged 2 years and older with pulmonary arterial hypertension, as described in the US label of Uptravi
The same US label of Uptravi separately lists treating pulmonary arterial hypertension (PAH, WHO Group I) in pediatric patients aged two years and older. The label says Uptravi reduces NT-proBNP and is expected to delay disease progression and lower the risk of hospital admission for PAH.Limitations. The label words the pediatric benefit as expected, and this claim keeps that wording. It is not a finding about how well the medicine works in children. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement. The adult indication sits in a separate claim.
Record details
- Record id
cardio:selexipag- Content hash
540800dee242798c7b82bf40066d44f36c89bcab18746ed3e9dcdeaee5ae1385